GlassScriptPhysician profile
Nathan T Gilmore
NPI 1275725897
$90,490.69
in general payments reported to CMS, 2019-2025
19 companies · $7,353 in 2025
The $7,353 reported for 2025 was more than what 99% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,444 · 2020: $1,352 · 2021: $18K · 2022: $25K · 2023: $17K · 2024: $12K · 2025: $7,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Honoraria: $8,438 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,208 · Travel and Lodging: $3,144 · Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,162.84 |
| Honoraria | $8,437.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,207.80 |
| Travel and Lodging | $3,143.97 |
| Food and Beverage | $1,575.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $30,398.18 | 2021-2025 | Accucath, Pristine, Powerpicc |
| Bard Access Systems, INC. | $26,293.43 | 2020-2023 | |
| Abiomed | $18,129.52 | 2019-2025 | Impella |
| Eagle Pharmaceuticals, INC. | $8,175.66 | 2022 | |
| Bard Peripheral Vascular, INC. | $5,384.74 | 2019 | |
| Penumbra, INC. | $485.48 | 2025 | Indigo System |
| La Jolla Pharmaceutical Company | $241.50 | 2019-2023 | Giapreza |
| Teleflex LLC | $239.48 | 2021-2025 | Arrow |
| Chiesi USA, INC. | $228.98 | 2020 | |
| Janssen Pharmaceuticals, INC | $225.32 | 2021-2024 | Spravato |
| Haemonetics Corporation | $194.68 | 2020-2021 | |
| Shionogi INC | $125.79 | 2024 | Fetroja |
| Abbvie INC. | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.19 | 2021 | |
| Fresenius USA Marketing, INC. | $44.00 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $27.64 | 2025 | Tempus Pixel |
| Livanova USA, INC. | $18.77 | 2022 | |
| Smith+Nephew, INC. | $18.43 | 2025 | Tc-100 |
| Csl Behring | $17.90 | 2023 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.